Abstract: To analyze the clinicopathologic features and prognosis of triple-negative breast cancer ( TNBC ). Methods: Clinical data from 333 operable patients that were histopathologically confirmed in the Xinjiang Cancer Hospital from January 2002 to December 2003 were analyzed. The patients were divided into two groups according to the results of immunohistochemical staining. One group was the triple negative breast cancer ( TNBC ), which included estrogen receptor ( ER ) negative, progesterone receptor ( PR ) negative, and human epidermal growth factor receptor ( HER2 ) negative, and the other was the non-triple-negative breast cancer group. The clinicopathologic features, local recurrence and metastasis, and 5-year disease-free rates were compared between the two groups. Results: Of the 333 patients, 82 ( 24.62% ) were confirmed as triple-negative breast cancer. The lymph node positive rate in the triple negative breast cancer patients was 41.5%. During follow-up, 21 cases ( 25.61% ) had local recurrence and metastasis occurred in 82 triple-negative breast cancer patients, whereas 38 cases ( 15.14% ) had local recurrence and metastasis among the 251 non-triple-negative breast cancer patients. Compared with the non-triple-negative breast cancer group, the hazard rate of distant metastasis in triple negative breast cancer group was 2.041 ( P = 0.015 ), the hazard rate of lung metastasis was 2.551 ( P = 0.036 ). The hazard rate of recurrence and metastatic risk within 3 years after the operation was 1.948 ( P = 0.042 ). Survival analysis showed that 5-year disease-free rates of triple negative breast cancer and non-triple-negative breast cancer were 74.4% and 84.9%, respectively. The comparison of two curves in the two groups: Log rank = 4.904, P = 0.027. Conclusion: The positive rate of the lymph nodes was higher in the triple-negative breast cancer. The risk of local recurrence and metastasis is higher in the triple-negative groups, which mainly manifests that the risk of distant metastasis is higher in the TNBC group. In other words, the risk of lung metastasis is higher in triple-negative breast cancer patients, and the risk of recurrence and metastasis is high within 3 years after operation. The 5-year disease-free survival ( DFS ) rate was lower in triple-negative breast cancer patients than in non-triple-negative breast cancer patients. TNBC has poor clinical prognosis.